Nuccardiac Software, Inc.
United StatesFDA applicant, unverified
- Devices
- 12
What Nuccardiac Software, Inc. makes
Nuccardiac Software, Inc. develops clinical diagnostic software for quantitative analysis of cardiac imaging, including tools for interpreting thallium-201 scans and Cardiolite® studies. Their products automate the measurement and assessment of myocardial perfusion, aiding in the diagnosis of coronary artery disease and cardiac function evaluation. These solutions are designed to run on specific medical imaging systems, such as the Medasys Digital Systems computer.
The company’s portfolio includes Class I and Class II devices under FDA regulation, with submissions recorded in the 510(k) premarket notification database. These products are intended for use in diagnostic imaging workflows and are listed in the U.S. regulatory system. The company is based in the United States.
Catalogue
Search and filter all 12 devicesFrequently asked questions
How many devices does Nuccardiac Software, Inc. have in the registry?
The registry currently lists 12 devices for Nuccardiac Software, Inc.. Devices recorded under merged duplicate company entries are counted once.
Which registries list Nuccardiac Software, Inc.'s devices?
Among its 12 most recently registered devices, Nuccardiac Software, Inc. has devices listed in FDA 510(k) (12 devices).
What risk classes do Nuccardiac Software, Inc.'s devices fall under?
Among its 12 most recently registered devices, the classes recorded for Nuccardiac Software, Inc.'s devices are Class I and Class II. Each device page shows its own class and authorisation.
What are the newest devices from Nuccardiac Software, Inc. in the registry?
The most recently registered devices listed for Nuccardiac Software, Inc. include CLINICAL DIAGNOSTIC SOFTWARE, CEQUAL(TM) QUANITATIVE ANALYSIS CARDIOLITE(R) SPEC, CTQ - CEDARS-SINAI QUANTITATIVE THALLIUM-201 ANALY and CEQUAL-QUANTITATIVE ANALYSIS.